Here are the 10-K annual reports from Arcus Biosciences, Inc. (RCUS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RCUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCUS filings page.
Arcus Biosciences is a late clinical-stage biopharmaceutical company developing small‑molecule and antibody therapies for cancer and inflammatory and autoimmune diseases. It remains loss‑making and expects significant future losses as it funds extensive research and clinical trials.
The lead oncology asset, casdatifan (HIF‑2α inhibitor), has shown improved efficacy versus belzutifan in late‑line renal cell carcinoma and is in a Phase 3 trial (PEAK‑1) with more Phase 3 work planned. Quemliclustat is in a fully enrolled Phase 3 pancreatic cancer study with results expected in the first half of 2027. TIGIT antibody domvanalimab saw one major gastrointestinal Phase 3 study stopped for futility, but lung cancer trials continue. Arcus is also advancing an oral inflammation pipeline, including MRGPRX2 and TNF programs, with first clinical studies targeted around 2026.
The company relies heavily on strategic partnerships, notably a broad multi‑program collaboration with Gilead that includes options, co‑development, co‑promotion and royalties, and regional licensing with Taiho. It highlights substantial risks around funding needs, clinical and regulatory outcomes, dependence on collaborators and manufacturers, intellectual property protection, competition, cybersecurity and evolving healthcare regulation.